Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9685024 | 0.83 | SHBG (0.50) | SHBGPGK1PGK2CYP2D6CYP2C9 | |
| SCHEMBL394846 | 0.76 | SHBG (0.48) | SHBGPGK1PGK2HIF1AHSD17B10 | |
| SCHEMBL23049664 | 0.76 | CYP2C9 (0.38) | SHBGCYP2D6CYP2C9CYP2C19HIF1A | |
| SCHEMBL5097086 | 0.75 | SHBG (0.52) | SHBGPGK1PGK2HIF1AHSD17B10 | |
| SCHEMBL24226063 | 0.75 | ESR1 (0.47) | SHBGHSD17B10KLF10ESR1 | |
| SCHEMBL17013416 | 0.74 | ESR1 (0.45) | SHBGHSD17B10KLF10ESR1 | |
| SCHEMBL26038933 | 0.71 | ALDH1A1 (0.46) | HIF1AHSD17B10 | |
| SCHEMBL28472333 | 0.70 | SHBG (0.48) | SHBGPGK1PGK2CYP2D6CYP2C9 | |
| SCHEMBL5075167 | 0.70 | SHBG (0.54) | SHBGPGK1PGK2CYP2D6CYP2C9 | |
| SCHEMBL25491039 | 0.70 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207741-A1 | Activation of the Renin-Angiotensin System (RAS) and Sudden Cardiac Death | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207741-A1 | Activation of the Renin-Angiotensin System (RAS) and Sudden Cardiac Death | GJA1, RASGRP1, RASGRP3 | SHBG 3947/4885PGK1 2635/4885PGK2 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.